Department of Medicine, University of California, Los Angeles, California.
Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
J Urol. 2022 Jun;207(6):1246-1255. doi: 10.1097/JU.0000000000002438. Epub 2022 Jan 21.
We assessed the reliability and validity of an efficient severity assessment for pelvic pain and urinary symptoms in urological chronic pelvic pain syndrome, which consists of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome.
A total of 578 patients were assessed using brief, empirically derived self-report scales for pelvic pain severity (PPS) and urinary symptom severity (USS) 4 times during a 1-month period and baseline clinic visit that included urological, pain and illness-impact measures. Mild, moderate and severe categories on each dimension were examined for measurement stability and construct validity.
PPS and USS severity categories had adequate reliability and both discriminant validity (differential relationships with specific clinical and self-report measures) and convergent validity (common association with nonurological somatic symptoms). For example, increasing PPS was associated with pelvic tenderness and widespread pelvic pain, whereas USS was associated with urgency during a bladder filling test and increased sensory sensitivity. PPS and USS categories were independently associated with nonurological pain and emotional distress. A descriptive analysis identified higher likelihood characteristics associated with having moderate to severe PPS or USS or both. Lack of sex interactions indicated that the measures are comparable in interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome.
Women and men with urological chronic pelvic pain syndrome can be reliably subgrouped using brief self-report measures of mild, moderate or severe pelvic pain and urinary symptoms. Comparisons with a broad range of clinical variables demonstrate the validity and potential clinical utility of these classifications, including use in clinical trials, health services and biological research.
我们评估了一种用于评估泌尿系统慢性盆腔疼痛综合征(包括间质性膀胱炎/膀胱疼痛综合征和慢性前列腺炎/慢性盆腔疼痛综合征)中盆腔疼痛和泌尿系统症状严重程度的有效评估方法的可靠性和有效性,该方法由简短的、经验衍生的自我报告的盆腔疼痛严重程度(PPS)和泌尿系统症状严重程度(USS)量表组成,在 1 个月期间和基线临床就诊期间共评估了 578 例患者,包括泌尿科、疼痛和疾病影响的测量。在每个维度上检查轻度、中度和重度类别,以评估测量稳定性和结构有效性。
在 1 个月期间和基线临床就诊期间,共评估了 578 例患者,使用简短的、经验衍生的自我报告的盆腔疼痛严重程度(PPS)和泌尿系统症状严重程度(USS)量表 4 次,包括泌尿科、疼痛和疾病影响的测量。在每个维度上检查轻度、中度和重度类别,以评估测量稳定性和结构有效性。
PPS 和 USS 严重程度类别具有足够的可靠性,并且具有鉴别效度(与特定的临床和自我报告测量的差异关系)和收敛效度(与非泌尿系统躯体症状的共同关联)。例如,PPS 的增加与盆腔压痛和广泛的盆腔疼痛有关,而 USS 与膀胱充盈试验期间的尿急和感觉敏感性增加有关。PPS 和 USS 类别与非泌尿系统疼痛和情绪困扰独立相关。描述性分析确定了与中度至重度 PPS 或 USS 或两者相关的更高可能性特征。缺乏性别交互作用表明,这些措施在间质性膀胱炎/膀胱疼痛综合征和慢性前列腺炎/慢性盆腔疼痛综合征中是可比的。
患有泌尿系统慢性盆腔疼痛综合征的女性和男性可以使用简单的自我报告测量方法对轻度、中度或重度盆腔疼痛和泌尿系统症状进行可靠的亚组分类。与广泛的临床变量进行比较,证明了这些分类的有效性和潜在的临床实用性,包括在临床试验、卫生服务和生物研究中的应用。